Skip to main content
. 2014 Nov 27;7:2175–2181. doi: 10.2147/OTT.S70654

Figure 3.

Figure 3

PFS (A) and OS (B) stratified by hormone therapy use in the continuation treatment phase (yes versus no) in the subgroup with estrogen receptor-positive disease.

Notes: *In the hormone-therapy group, the OS median was not reached (immature data); 56.3 months was the maximum value recorded in this group.

Abbreviations: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.